Prodia Diagnostic Line is trading 3.52% down at IDR 274 as investors continue digesting weak first-half 2026 results.
- Revenue fell 51.9% year over year to IDR 13.7 billion, while the company posted an IDR 8.8 billion net loss.
- The decline follows substantial post-IPO volatility, including an exchange-monitored unusual trading pattern.
- No new August 11 company announcement was found; earnings disappointment and technical selling remain the most plausible explanation.